UNSPSC 51413212: Vardenafil hydrochloride hydrate

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular formula C23H32N6O4S.ClH.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5M8S2CU0TS, chemically known as imidazo(5,1-f)(1,2,4)triazin-4(1h)-one, 2-(2-ethoxy-5-((4-ethyl-1-piperazinyl)sulfonyl)phenyl)-5-methyl-7-propyl-, hydrochloride, hydrate (1:1:3), but more generally known as vardenafil hydrochloride hydrate, which bears US NIH Compound Identifier 6918463.

European Medicines Agency schedules vardenafil hydrochloride hydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20047. Most nations, for tariff purposes, schedule vardenafil hydrochloride hydrate under HS 29350090. SMILES: CCCC1NC(C2N1[NH]C(NC2=O)C3CC(CCC3OCC)S(=O)(=O)N4CCN(CC4)CC)C.O.O.O.CL.

UNSPSC 51413212 Vardenafil hydrochloride hydrate is a Commodity code covering pharmaceutical active ingredients and finished medications purchased by state and local health agencies, emergency services, and health benefit programs. State and local governments buy this medication and related pharmaceuticals for emergency medical services, institutional pharmacy programs, and state health benefit administration — actual recent procurement focuses on advanced life support medications for emergency response, generic pharmaceutical sourcing for multi-state cooperative purchasing, and direct-to-manufacturer pharmacy benefit initiatives. Issuing bodies include municipal fire rescue departments, state health and human services agencies, and multi-state cooperative purchasing alliances that aggregate demand across participating jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) on April 24, 2026, for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling the state's intent to establish direct contracting relationships with pharmaceutical manufacturers outside traditional PBM and GPO channels.